Amicus Therapeutics has provided our community with a statement in an effort to keep us informed about their operations. We understand that the landscape is changing every day as the industry, and countries in general, adjust to the outbreak.

At this time, patients participating in all clinical studies for AT-GAA for Pompe disease, including the Phase 3 PROPEL study, can expect it to be uninterrupted. Each patient’s situation is being addressed to accommodate any concerns. Amicus is in constant contact with study site staff to develop contingency plans when needed. This could involve infusion site changes, home infusions or other changes.

The letter to our community is below:

Source: COVID-19 Amicus Patient Comms FINAL

Tagged: chaperone, clinical trials, COVID-19, ERT